GlobeNewswire Inc | Mar 9, 2021 07:00AM EST

March 09, 2021

BOTHELL, Wash., March 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.(Nasdaq: COCP), (Cocrystal or the Company), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management will hold one-on-one investor meetings at the Virtual 33rd Annual Roth Conference being held March 15-17, 2021. A webcast of Cocrystals presentation has been pre-recorded and is available on the Companys website here.

Investors interested in arranging a virtual meeting with Cocrystal management should contact their Roth Capital Partners sales representative or LHA Investor Relations. Roth Conference information is available here.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visitwww.cocrystalpharma.com.

Investor Contact:LHA Investor RelationsJody Cain310-691-7100jcain@lhai.com

# # #